Concord Wealth Partners’s Blueprint Medicines BPMC Stock Holding History

Concord Wealth Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$128	–	840
2025 Q2	$128	Buy	+1	New	+$104	﹤0.01%	825
2022 Q3	–	Sell	-25	Closed	-$1K	–	278
2022 Q2	$1K	Hold	25	–	–	﹤0.01%	1104
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	1070
2021 Q4	$3K	Hold	25	–	–	﹤0.01%	1031
2021 Q3	$3K	Hold	25	–	–	﹤0.01%	668
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	870
2021 Q1	$2K	Hold	25	–	–	﹤0.01%	805
2020 Q4	$3K	Buy	+25	New	+$2.63K	﹤0.01%	459

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Concord Wealth Partners's BPMC Position: Q3 2025 in Review

Concord Wealth Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1 share — an estimated $128 sold.

Concord Wealth Partners first reported a position in BPMC in Q4 2020 and held it in 8 quarters. The position peaked at $3K in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Concord Wealth Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Concord Wealth Partners sold 1 Blueprint Medicines share in Q3 2025, an estimated $128.
Concord Wealth Partners first reported a position in Blueprint Medicines in Q4 2020 and held it in 8 quarters.
Concord Wealth Partners's Blueprint Medicines position peaked at $3K in Q4 2021.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Concord Wealth Partners's 13F filing for Q3 2025, filed 5 Nov 2025.